• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Optomed

1.73 EUR+1.76 %10.7, 16.00
5,666 following

OPTOMED

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Dividend
Investor consensus
Compare
+1.76 %
+19.97 %
-25.43 %
-52.86 %
-54.11 %
-58.41 %
-49.86 %
-89.45 %
-62.23 %

Optomed operates in the medical technology sector. The company conducts research and development of specialized eye cameras. Development takes place of both hardware and software that are resold under different brands. Operations are held on a global level, with the largest presence in the Nordic market. Customers consist of research institutes and hospitals. The company has its headquarters in Oulu.

Read more
Market cap
37.11M EUR
Turnover
53.68K EUR
P/E (adj.) (26e)
-12.8
EV/EBIT (adj.) (26e)
-9.67
P/B (26e)
1.76
EV/S (26e)
1.82
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
2.00 EUR
Updated
07.05.2026
Disclaimer
Juha Kinnunen
Juha Kinnunen

Analyst

Latest research

Latest analysis report

Released: 07.05.2026

Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
Somehow, I’m starting to believe in what AEYE Health is doing/selling. In the background, there is the new $50 billion Rural Health Transformation Program (RHTP), which was established by the One Big Beautiful Bill Act (Public Law 119-21) and is being distributed by CMS to the states...
7/7/2026, 7:55 PM
by Mr. Stock
31
I’ve been digging up and reading a lot of material related to Optomed, but somehow this had escaped my notice. I couldn’t find it here with a quick search either… the text was put together in collaboration with AI. Digi4Care is a pilot project implemented in Croatia, where diabetic...
7/2/2026, 6:20 PM
by Artoh1
31
A small detail, but it shows that in Chicago they know what’s good. There are five locations, all of which are implementing fundus photography. LinkedIn #diabetes #healthcare #wellness | Wellness Homes of Chicago RETINA SCREENING FOR DIABETIC PATIENTS AT ALL OUR LOCATIONS. We believe...
7/7/2026, 7:57 AM
28
Revenio/Icare’s partner iHealthscreen has now received FDA approval for their algorithm and the Icare DRSplus camera combo. We have gained a strong new player to expand the AI market. This is also good news for Optomed; AI will be offered more and more actively in a market where ...
7/7/2026, 5:15 AM
by Sheikki
26
LinkedIn Translating AI Into the Eye Clinic | Tien Yin Wong FRS 黄天荫 Our first presentation of the concepts and initial lessons of the AI-Agent Augmented Tsinghua Eye Clinic (AI-TEC), just published in JAMA Ophthalmology. More to come! Tsinghua University Tsinghua Medicine 清华大学医学院...
7/5/2026, 11:08 AM
by Mr. Stock
23
We may soon hear news from Kentucky as well. In the comments section of this AEYE post: Over 60% of patients with diabetes skip their annual diabetic eye exam. In rural America, that gap is often even wider because the nearest retina specialist can be hours away, transforming a routine...
yesterday
by Mr. Stock
16
Interestingly, the authors of the above study refer to a previous study in which 21 different AI algorithms were compared using images taken with Optomed’s handheld camera, which indicates that Aurora has been used as a validation platform for AI screening. So, when following the...
7/3/2026, 7:23 AM
by Dr.Feelgood
15
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
14.8
2026

Interim report Q2'26

6.11
2026

Interim report Q3'26

Press release23.06.2026, 09.43

Redeye: Optomed: Solid device order

Optomed
Optomed modtog en udstyrsordre på 1,8 MEUR fra USA
Analyst Comment22.06.2026, 06.58 by
Atte Riikola

Optomed modtog en udstyrsordre på 1,8 MEUR fra USA

Ordren overstiger hele årets første halvårs omsætning for udstyr og styrker pengestrømmen.

Optomed
Regulatory press release18.06.2026, 16.30

Inside Information: Optomed receives a large order in the US

Optomed

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release11.05.2026, 15.16

Redeye: Optomed (Q1 Interview): Expecting normalised sales in upcoming quarters

Optomed
Regulatory press release08.05.2026, 19.00

Optomed Oyj: Decisions of the Organization Meeting of Optomed's Board of Directors

Optomed
Regulatory press release08.05.2026, 13.30

Optomed Oyj: Decisions of the Annual General Meeting

Optomed
Press release08.05.2026, 10.10

Redeye: Optomed (Q1 Review): Soft sales weigh on sentiment

Optomed
Optomed Q1'26: Bunden forsvandt fra væksten og aktien
Research07.05.2026, 07.00 by
Juha Kinnunen

Optomed Q1'26: Bunden forsvandt fra væksten og aktien

Væksten i Optomeds kritiske Udstyr-segment var langt under vores forventninger i Q1, og at dømme ud fra kursreaktionen, løb investorerne tør for tålmodighed.

Optomed
Press release06.05.2026, 10.51

Redeye: Optomed (Q1 Initial take): Softer quarter than expected

Optomed
Regulatory press release06.05.2026, 08.00

Optomed Oyj: Optomed Plc: Interim report January - March 2026

Optomed
Optomed Q1'26 preview: Vi forventer fremskridt i udstyrssegmentet
Analyst Comment04.05.2026, 06.00 by
Juha Kinnunen

Optomed Q1'26 preview: Vi forventer fremskridt i udstyrssegmentet

Vi forventer, at Devices-segmentet voksede med over 13 procent, understøttet af Aurora AEYE-løsningen og Lumo-kameraet.

Optomed
Regulatory press release09.04.2026, 12.00

Optomed Oyj: Notice Of The Annual General Meeting Of Optomed Plc

Optomed
US market roadmap for medical devices – a European perspective
Analyst Comment27.03.2026, 11.45 by
Antti Siltanen

US market roadmap for medical devices – a European perspective

Success in the US requires success in several sub-areas.

BioretecAiforia TechnologiesNightingale HealthNexstimOptomedRevenio GroupModulightBiohit
Regulatory press release27.02.2026, 08.00

Optomed Oyj: Disclosure under Chapter 9, Section 10 of the Securities Markets Act regarding change in holdings

Optomed
Regulatory press release25.02.2026, 08.00

Optomed Oyj: Optomed Annual Report 2025 published

Optomed
Press release11.02.2026, 13.31

Redeye: Optomed Q4 (Review): Devices segment supports outlook despite cautious guidance

Optomed
Optomed Q4'25: Vækstselskaber skal levere vækst
Research11.02.2026, 07.00 by
Juha Kinnunen

Optomed Q4'25: Vækstselskaber skal levere vækst

Optomeds vækstforventninger for 2026 var svage, hvilket fik markedet til at skære en fjerdedel af aktiens værdi.

Optomed
Press release10.02.2026, 13.16

Redeye: Optomed Q4 (Initial take): Sales in line; EBIT impacted by a one-off cost

Optomed
Regulatory press release10.02.2026, 08.00

Optomed Oyj: Optomed Plc: Financial Statements Bulletin January - December 2025

Optomed
Optomed Q4'25 preview: Fokus på forventninger
Analyst Comment06.02.2026, 05.06 by
Juha Kinnunen

Optomed Q4'25 preview: Fokus på forventninger

Optomed offentliggør sit Q4 regnskab næste tirsdag. Hovedfokus i regnskabet er rettet mod omsætningsvækstprognosen for 2026, som vi forventer vil være i form af "stærk vækst". Vores opmærksomhed i regnskabsmeddelelsen er især rettet mod den kommercielle udvikling af vækstfaktorerne i Udstyr-segmentet, såsom Aurora AEYE-løsningen og Optomed Lumo.

Optomed